Every week, HealthXL communities connect to break down some of the major challenges and opportunities in digital health.
If you are interested in joining any of these meetings, just click through the link to request access. However, even if you can't make a meeting, keep an eye out for the key takeaways, which will be published later this month.
20 June - Digital Biomarkers in Clinical Trials: Do’s & Don’ts in the Validation Process
Novel digital biomarkers have the potential to be part of clinical trials, but there are still a lot of questions regarding their reliability and validation process. If you you struggling with validating these digital biomarkers, we will be breaking down the issues
21 June - Masterclass: The regulation of SaMD in the EU
Regulation is an absolute essential for digital health companies who want to be accepted into clinical and payer groups. What are the must know and do’s and don’ts when attempting to take your SaMD product through regulatory path?
You can join this meeting here.
21 June - Masterclass: How to design a Clinical Trial for your Digital Health product?
Are you struggling with trial design for your digital health products? Proving clinical efficacy is one of the biggest challenges for digital health companies. However, it is key to getting buy-in from stakeholders. How can we design trials for digital health tools so they are rigorously validated and regulated?
22 June - Telehealth platforms as a distribution channel for DTx and RPM products
Over the last few months, the industry has begun to recognize the importance of shifting to a more patient-centric approach. Can telehealth platforms be a hub for digital therapeutics (DTx) and remote patient monitoring (RPM) solutions?
If you are interested in joining any of these meetings, just click through the link to request access. However, even if you can't make a meeting, keep an eye out for the key takeaways, which will be published later this month.
20 June - Digital Biomarkers in Clinical Trials: Do’s & Don’ts in the Validation Process
Novel digital biomarkers have the potential to be part of clinical trials, but there are still a lot of questions regarding their reliability and validation process. If you you struggling with validating these digital biomarkers, we will be breaking down the issues
21 June - Masterclass: The regulation of SaMD in the EU
Regulation is an absolute essential for digital health companies who want to be accepted into clinical and payer groups. What are the must know and do’s and don’ts when attempting to take your SaMD product through regulatory path?
You can join this meeting here.
21 June - Masterclass: How to design a Clinical Trial for your Digital Health product?
Are you struggling with trial design for your digital health products? Proving clinical efficacy is one of the biggest challenges for digital health companies. However, it is key to getting buy-in from stakeholders. How can we design trials for digital health tools so they are rigorously validated and regulated?
22 June - Telehealth platforms as a distribution channel for DTx and RPM products
As the digital health industry grows exponentially, patients and providers are being flooded by hundreds of digital health products. For patients, particularly those with multiple comorbidities, it presents a problem of having to use different digital health products for every condition.
Over the last few months, the industry has begun to recognize the importance of shifting to a more patient-centric approach. Can telehealth platforms be a hub for digital therapeutics (DTx) and remote patient monitoring (RPM) solutions?